细胞色素P450 2D6、3A4和19A1基因多态性与乳腺癌的药物治疗  

Cytochrome P450 2D6,3A4 and 19A1:gene polymorphism and drug therapy of breast cancer

作　　者：李璐[1,2] 王明霞[1] 赵宝华[2] 

机构地区：[1]河北医科大学第四医院 [2]河北师范大学生命科学学院,河北石家庄050011

出　　处：《中国药理学通报》2013年第3期311-314,共4页Chinese Pharmacological Bulletin

基　　金：河北省卫生厅医学科学研究重点课题项目(No20100122);河北省人力资源和社会保障厅留学回国人员科技活动择优资助项目(No 20100313)

摘　　要：细胞色素P450(CYP)是一种重要的氧化代谢酶,参与多种药物的代谢。CYP酶具有基因多态性,对药物的代谢呈现明显的差异,对乳腺癌用药也有差异性影响。该文主要阐述细胞色素P450 2D6、3A4和19A1亚型的多态性,并就其多态性对临床乳腺癌治疗中重要的药物如他莫昔芬、芳香化酶抑制剂、紫杉醇类在治疗学方面的影响进行综述。The cytochrome P450（CYP）,as an important enzyme of oxidative metabolism,is involed in metabolism of a variety of drugs.The polymorphic nature of CYP genes show obvious differences in metabolism of drugs,and also have an effect on drug responses of breast cancer therapy.This article focuses on the polymorphisms of cytochrome P450 2D6,3A4 and 19A1 subtype,and reviews the effects of their polymorphisms on the major drugs in clinical breast cancer drug therapy,including tamoxifen,aromatase inhibitors,docetaxel and paclitaxel.

关 键 词：细胞色素P450 基因多态性 药物治疗 乳腺癌 他莫昔芬 芳香化酶抑制剂 紫杉醇 多西紫杉醇 

分 类 号：R-05[医药卫生] R345.99